



Last Patient Completes Treatment in Phase 2 Clinical Trial for Venous Leg Ulcer Healing

Brisbane, Australia 4th October 2018: Factor Therapeutics Limited (ASX: FTT, the “Company”), an Australian biomedical company developing therapeutics for advanced wound care, is pleased to announce that all patients have completed treatment in the Company’s Phase 2 clinical trial, VF00102, for venous leg ulcer (VLU) healing.

The Company expects to release top-line results in mid-November, following final quality checks and database analysis.

Dr. Ros Wilson, CEO of Factor Therapeutics, said, “The last treatment visit took place overnight in the US, a little ahead of schedule - we’re delighted to have reached this important milestone. A huge thank you to all of our patients for agreeing to be part of the trial. We’re now only a matter of weeks away from readout and are continuing, in the meantime, with partnering discussions and preparations for regulatory interactions in Europe and the US next year.”

-ENDS-

Contact for Further Information:

Dr. Rosalind Wilson
Chief Executive Officer
Factor Therapeutics Limited
r.wilson@factor-therapeutics.com

About Factor Therapeutics

Factor Therapeutics Limited (“Factor”) is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company’s platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor’s shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <https://factor-therapeutics.com>